Cargando…

Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission

The prevalence of inflammatory bowel disease (IBD) has increased worldwide. The prevalence of metabolic dysfunction associated fatty liver disease (MAFLD) has also risen. However, there is limited research on the connection between MAFLD and IBD in the Asian population. This study aims to analyze th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Shun-Wen, Chen, Ting-Chun, Su, Pei-Yuan, Yang, Chen-Ta, Huang, Siou-Ping, Chen, Yang-Yuan, Yen, Hsu-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606634/
https://www.ncbi.nlm.nih.gov/pubmed/37892089
http://dx.doi.org/10.3390/diagnostics13203268
_version_ 1785127363044966400
author Hsiao, Shun-Wen
Chen, Ting-Chun
Su, Pei-Yuan
Yang, Chen-Ta
Huang, Siou-Ping
Chen, Yang-Yuan
Yen, Hsu-Heng
author_facet Hsiao, Shun-Wen
Chen, Ting-Chun
Su, Pei-Yuan
Yang, Chen-Ta
Huang, Siou-Ping
Chen, Yang-Yuan
Yen, Hsu-Heng
author_sort Hsiao, Shun-Wen
collection PubMed
description The prevalence of inflammatory bowel disease (IBD) has increased worldwide. The prevalence of metabolic dysfunction associated fatty liver disease (MAFLD) has also risen. However, there is limited research on the connection between MAFLD and IBD in the Asian population. This study aims to analyze the prevalence and clinical significance of MAFLD in Taiwanese IBD patients with clinical remission. We retrospectively analyzed IBD patients who received transient elastography for liver fibrosis and controlled attenuation parameter evaluation for liver steatosis. This study enrolled 120 patients with IBD, including 45 Crohn’s disease (CD) and 75 ulcerative colitis (UC). MAFLD prevalence in IBD was 29.2%. Patients with MAFLD had a shorter disease duration (2.8 years vs. 5.3 years, p = 0.017), higher alanine aminotransferase levels (24 U/L vs. 17 U/L, p = 0.003), a lower estimated glomerular filtration rate (91.37 mL/min/1.73 m(2) vs. 103.92 mL/min/1.73 m(2), p = 0.004), and higher γ-glutamyl transferase (γ-GT) (24 mg/dL vs. 13 mg/dL, p < 0.001). The prevalence of significant fibrosis in IBD with MAFLD was 17.1%. Significant fibrosis was found in older age (58.5 years vs. 40 years, p = 0.004) and the high type 2 diabetes mellitus proportion (50.0% vs. 10.3%, p = 0.049). A trend of longer disease duration was found in significant fibrosis (4.9 years vs. 1.6 years, p = 0.051). The prevalence of MALFD in IBD was 29.2%. and 17.1% of them had significant fibrosis. In addition to the intestinal manifestation, the study findings remind clinicians that they should be aware of the possibility of hepatic complications for IBD patients.
format Online
Article
Text
id pubmed-10606634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106066342023-10-28 Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission Hsiao, Shun-Wen Chen, Ting-Chun Su, Pei-Yuan Yang, Chen-Ta Huang, Siou-Ping Chen, Yang-Yuan Yen, Hsu-Heng Diagnostics (Basel) Article The prevalence of inflammatory bowel disease (IBD) has increased worldwide. The prevalence of metabolic dysfunction associated fatty liver disease (MAFLD) has also risen. However, there is limited research on the connection between MAFLD and IBD in the Asian population. This study aims to analyze the prevalence and clinical significance of MAFLD in Taiwanese IBD patients with clinical remission. We retrospectively analyzed IBD patients who received transient elastography for liver fibrosis and controlled attenuation parameter evaluation for liver steatosis. This study enrolled 120 patients with IBD, including 45 Crohn’s disease (CD) and 75 ulcerative colitis (UC). MAFLD prevalence in IBD was 29.2%. Patients with MAFLD had a shorter disease duration (2.8 years vs. 5.3 years, p = 0.017), higher alanine aminotransferase levels (24 U/L vs. 17 U/L, p = 0.003), a lower estimated glomerular filtration rate (91.37 mL/min/1.73 m(2) vs. 103.92 mL/min/1.73 m(2), p = 0.004), and higher γ-glutamyl transferase (γ-GT) (24 mg/dL vs. 13 mg/dL, p < 0.001). The prevalence of significant fibrosis in IBD with MAFLD was 17.1%. Significant fibrosis was found in older age (58.5 years vs. 40 years, p = 0.004) and the high type 2 diabetes mellitus proportion (50.0% vs. 10.3%, p = 0.049). A trend of longer disease duration was found in significant fibrosis (4.9 years vs. 1.6 years, p = 0.051). The prevalence of MALFD in IBD was 29.2%. and 17.1% of them had significant fibrosis. In addition to the intestinal manifestation, the study findings remind clinicians that they should be aware of the possibility of hepatic complications for IBD patients. MDPI 2023-10-20 /pmc/articles/PMC10606634/ /pubmed/37892089 http://dx.doi.org/10.3390/diagnostics13203268 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsiao, Shun-Wen
Chen, Ting-Chun
Su, Pei-Yuan
Yang, Chen-Ta
Huang, Siou-Ping
Chen, Yang-Yuan
Yen, Hsu-Heng
Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title_full Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title_fullStr Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title_full_unstemmed Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title_short Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
title_sort metabolic dysfunction-associated fatty liver disease in taiwanese patients with inflammatory bowel disease: a study in patients with clinical remission
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606634/
https://www.ncbi.nlm.nih.gov/pubmed/37892089
http://dx.doi.org/10.3390/diagnostics13203268
work_keys_str_mv AT hsiaoshunwen metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT chentingchun metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT supeiyuan metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT yangchenta metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT huangsiouping metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT chenyangyuan metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission
AT yenhsuheng metabolicdysfunctionassociatedfattyliverdiseaseintaiwanesepatientswithinflammatoryboweldiseaseastudyinpatientswithclinicalremission